A detailed history of State Street Corp transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 687,577 shares of GLUE stock, worth $4.85 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
687,577
Previous 636,084 8.1%
Holding current value
$4.85 Million
Previous $2.38 Million 53.24%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.59 - $6.97 $184,859 - $358,906
51,493 Added 8.1%
687,577 $3.64 Million
Q2 2024

Aug 14, 2024

BUY
$3.38 - $7.86 $70,415 - $163,747
20,833 Added 3.39%
636,084 $2.38 Million
Q1 2024

May 15, 2024

BUY
$4.26 - $8.46 $178,246 - $353,983
41,842 Added 7.3%
615,251 $4.34 Million
Q4 2023

Feb 14, 2024

SELL
$2.5 - $5.93 $48,372 - $114,739
-19,349 Reduced 3.26%
573,409 $3.24 Million
Q3 2023

Nov 14, 2023

SELL
$4.78 - $7.22 $10,884 - $16,439
-2,277 Reduced 0.38%
592,758 $2.84 Million
Q2 2023

Aug 14, 2023

BUY
$4.53 - $8.4 $291,229 - $540,027
64,289 Added 12.11%
595,035 $4.08 Million
Q1 2023

May 15, 2023

BUY
$5.95 - $8.21 $79,551 - $109,767
13,370 Added 2.58%
530,746 $4.13 Million
Q4 2022

Feb 14, 2023

BUY
$6.71 - $9.72 $220,121 - $318,864
32,805 Added 6.77%
517,376 $3.94 Million
Q3 2022

Nov 15, 2022

BUY
$7.17 - $12.16 $241,679 - $409,877
33,707 Added 7.48%
484,571 $3.96 Million
Q2 2022

Aug 15, 2022

BUY
$6.15 - $14.99 $499,970 - $1.22 Million
81,296 Added 22.0%
450,864 $4.36 Million
Q1 2022

May 16, 2022

BUY
$10.36 - $20.41 $1.76 Million - $3.47 Million
169,992 Added 85.18%
369,568 $5.18 Million
Q4 2021

Feb 14, 2022

BUY
$16.28 - $27.15 $781,993 - $1.3 Million
48,034 Added 31.7%
199,576 $4.08 Million
Q3 2021

Nov 15, 2021

BUY
$18.59 - $42.21 $2.82 Million - $6.4 Million
151,542 New
151,542 $3.38 Million

Others Institutions Holding GLUE

About Monte Rosa Therapeutics, Inc.


  • Ticker GLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,713,900
  • Market Cap $329M
  • Description
  • Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...
More about GLUE
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.